Skip to Content

Tolmetin Pregnancy and Breastfeeding Warnings

Tolmetin is also known as: Tolectin, Tolectin 600, Tolectin DS

Medically reviewed by Last updated on May 28, 2020.

Tolmetin Pregnancy Warnings

Animal studies have failed to reveal evidence of teratogenicity or impaired fertility. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Not recommended during last trimester of pregnancy.
Prior to 30 weeks gestation: Use only if potential benefit justifies the potential risk to the fetus.

US FDA pregnancy category: C

-Avoid use in late pregnancy as it may cause premature closure of the ductus arteriosus.

See references

Tolmetin Breastfeeding Warnings

Due to its short half-life and low levels expressed in breast milk, it is unlikely that this drug will cause adverse effects in the breastfed infant. However, due to lack of published clinical experience in newborns and preterm infants, other agents may be preferred.

Caution is recommended.

Excreted into human milk: Yes

-The manufacturer recommends to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical, Raritan, NJ.

References for breastfeeding information

  1. "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical, Raritan, NJ.
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.